By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Research findings on Proteomics are discussed in a new report. According to news reporting from London, United Kingdom, by NewsRx journalists, research stated, "Non-viral vector formulations comprise typically complexes of nucleic acids with cationic polymers or lipids. However, for in vivo applications cationic formulations suffer from problems of poor tissue penetration, nonspecific binding to cells, interaction with serum proteins and cell adhesion molecules and can lead to inflammatory responses."
The news correspondents obtained a quote from the research from the Institute of Child Health, "Anionic for mulations may provide a solution to these problems but they have not been developed to the same extent as cationic formulations due to difficulties of nucleic acid packaging and poor transfection efficiency. We have developed novel PEGylated, anionic nanocomplexes containing cationic targeting peptides that act as a bridge between PEGylated anionic liposomes and plasmid DNA. At optimized ratios, the components self-assemble into anionic nanocomplexes with a high packaging efficiency of plasmid DNA. Anionic PEGylated nanocomplexes were resistant to aggregation in serum and transfected cells with a far higher degree of receptor-targeted specificity than their homologous non-PEGylated anionic and cationic counterparts. Gadolinium-labeled, anionic nanoparticles, administered directly to the brain by convection-enhanced delivery displayed improved tissue penetration and dispersal as well as more widespread cellular transfection than cationic formulations."
According to the news reporters, the research concluded: "Anionic PEGylated nanocomplexes have widespread potential for in vivo gene therapy due to their targeted transfection efficiency and ability to penetrate tissues."
For more information on this research see: PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes. Journal of Controlled Release, 2014;174():177-187. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news journalists report that additional information may be obtained by contacting A.D. Tagalakis, UCL, Inst Child Hlth, London WC1E 6DD, United Kingdom. Additional authors for this research include G.D. Kenny, A.S. Bienemann, D. McCarthy, M.M. Munye, H. Taylor, M.J. Wyatt, M.F. Lythgoe, E.A. White and S.L. Hart (see also Proteomics).
Keywords for this news article include: Biotechnology, London, Europe, Peptides, Proteins, Proteomics, Gene Therapy, United Kingdom, Bioengineering
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC